Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less

Journal of Clinical Oncology

Volumn 20, Issue 20, 2002, Pages 4141-4149

  Fisher, Bernard ^a   Bryant, John ^a   Dignam, James J ^a   Wickerham, D Lawrence ^a   Mamounas, Eleftherios P ^a   Fisher, Edwin R ^a   Margolese, Richard G ^a   Nesbitt, Lois ^a   Paik, Soonmyung ^a   Pisansky, Thomas M ^a   Wolmark, Norman ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PLACEBO; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG INDUCED DISEASE; ENDOMETRIUM CANCER; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RADIATION SICKNESS; SECOND CANCER; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT FAILURE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 0037108675     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.11.101     Document Type: Article

References (43)

1. Fisher B, Bauer M, Margolese R, et al: Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 312:665-673, 1985
2. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989
3. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
4. Fisher B, Wolmark N, Fisher ER, et al: Lumpectomy and axillary dissection for breast cancer: Surgical, pathological and radiation considerations. World J Surg 9:692-698, 1985
5. Gaynor JJ, Feuer EJ, Tan CC, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
6. Prentice RL, Kalbfleisch JD, Peterson AV, et al: The analysis of failure times in the presence of competing risks. Biometrics 34:541-554, 1978
7. Liljegren G, Holmberg L, Adami HO, et al: Sector resection with or without postoperative radiotherapy for stage I breast cancer: Five-year results of a randomized trial. J Natl Cancer Inst 86:717-722, 1994
8. Veronesi U, Luini A, Del Vecchio M, et al: Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 328:1587-1591, 1993
9. Clark RM, Whelan T, Levine M, et al: Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: An update. J Natl Cancer Inst 88:1659-1664, 1996
10. Forrest AP, Stewart HJ, Everington D, et al: Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Lancet 348:708-713, 1996
11. Renton SC, Gazet JC, Ford HT, et al: The importance of the resection margin in conservative surgery for breast cancer. Eur J Surg Cancer 22:17-22, 1996
12. Stewart HJ, Prescott RJ, Forrest PA: Conservation therapy of breast cancer. Lancet 2:168-169, 1989 (letter)
13. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993-2000, 1999
14. McCready DR, Hanna W, Kahn H, et al: Factors associated with local breast cancer recurrence after lumpectomy alone. Ann Surg Oncol 3:358-366, 1996
15. Elkhuizen PHM, van de Vijver MJ, Hermans J, et al: Local recurrence after breast-conserving therapy for invasive breast cancer: High incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys 40:859-867, 1998
16. Fowble B: Is there a subset of patients with early stage invasive breast cancer for whom irradiation may not be indicated after conservative surgery alone? Breast J 1:75-90, 1995 (review)
17. Fisher B, Redmond C: Lumpectomy for breast cancer: An update of the NSABP experience. J Natl Cancer Inst Monogr 11:7-13, 1992
18. Margreiter R, Wiegele J: Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer. Breast Cancer Res Treat 4:45-48, 1984
19. Nolvadex Adjuvant Trial Organisation: Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Lancet 1:836-840, 1985
20. Report from the Breast Cancer Trials Committee: Scottish Cancer Trials Office (MRC). Edinburgh: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 2:171-175, 1987
21. Fisher B, Redmond C, Brown A, et al: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial. J Clin Oncol 4:459-471, 1986
22. Fisher B, Dignam J, Tan-Chiu E, et al: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 93:112-120, 2001
23. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388, 1998
24. Rutqvist LE, Cedermark B, Glas U, et al: Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 83:1299-1306, 1991
25. Cancer Research Campaign Adjuvant Breast Trial Working Party: Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 57:604-607, 1988
26. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996
27. Fyles A, McCready D, Manchul L, et al: Preliminary results of a randomized study of tamoxifen +/- breast radiation in T1/2 NO disease in women over 50 years of age. Proc Am Soc Clin Oncol 20:24A, 2001 (abstr 92)
28. Hughes KS, Schnaper L, Berry D, et al: Comparison of lumpectomy plus tamoxifen with and without radiotherapy (RT) in women 70 years of age or older who have clinical stage I, estrogen receptor positive (ER+) breast carcinoma. Proc Am Soc Clin Oncol 20:24A, 2001 (abstr 93)
29. Liljegren G, Lindgren A, Bergh J, et al: Risk factors for local recurrence after conservative treatment in stage I breast cancer: Definition of a subgroup not requiring radiotherapy. Ann Oncol 8:235-241, 1997
30. Gruenberger T, Gorlitzer M, Soliman T, et al: It is possible to omit postoperative irradiation in a highly selected group of elderly breast cancer patients. Breast Cancer Res Treat 50:37-46, 1998
31. Veronesi U, Marubini E, Mariani L, et al: Radiotherapy after breast-conserving surgery in small breast carcinoma: Long-term results of a randomized trial. Ann Oncol 12:997-1003, 2001
32. Borger J, Kemperman H, Hart A, et al: Risk factors in breast-conservation therapy. J Clin Oncol 12:653-660, 1994
33. Silverstein MJ, Lagios MD, Groshen S, et al: The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 340:1455-1461, 1999
34. Holland PA, Gandhi A, Knox WF, et al: The importance of complete excision in the prevention of local recurrence of ductal carcinoma in situ. Br J Cancer 77:110-114, 1998
35. Obedian E, Haffty BG: Negative margin status improves local control in conservatively managed breast cancer patients. Cancer J Sci Am 6:28-33, 1999
36. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 90:1601-1608, 1998
37. Voogd AC, van Tienhoven G, Peterse HL, et al: Local recurrence after breast conservation therapy for early stage breast carcinoma: Detection, treatment, and outcome in 226 patients. Cancer 85:437-446, 1999
38. Osteen RT: Risk factors and management of local recurrence following breast conservation surgery. World J Surg 18:76-80, 1994
39. Dipaola RS, Orel SG, Fowble BL: Ipsilateral breast tumor recurrence following conservative surgery and radiation therapy. Oncology 8:59-68, 1994
40. Francis M, Cakir B, Ung O, et al: Prognosis after breast recurrence following conservative surgery and radiotherapy in patients with node-negative breast cancer. Br J Surg 86:1556-1562, 1999
41. Fisher B, Dignam J, Wolmark N, et al: Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441-452, 1998
42. Gelber RD, Goldhirsch A: Radiotherapy to the conserved breast: Is it avoidable if the cancer is small? J Natl Cancer Inst 86:652-654, 1994
43. Wong JS, Harris JR: Importance of local tumour control in breast cancer. Lancet Oncol 2:11-17, 2001